The FDA Removed the Boxed Warning on Testosterone. Here's What That Actually Means.

For more than a decade, the most severe warning the FDA can put on a drug sat on testosterone products. It told patients and doctors to worry about heart attack, stroke, and death. On February 28, 2025, the agency told manufacturers of every approved testosterone product to take that cardiovascular boxed-warning language off the label.

That is not the same thing as the FDA declaring TRT safe. I want to be as clear about that as I was in the menopause piece. The agency looked at a large cardiovascular trial that did not show an increase in major cardiac events in men treated for hypogonadism. It also looked at blood-pressure studies that did show a class-wide rise. So two things happened at once. A warning the trial did not support came off. A warning the blood-pressure studies did support went on.

If you were told no in 2015, or in 2019, or last year, this is the article I would want you to read. Not because the answer is now automatically yes. Because you deserve to know what the no was actually based on.

What the FDA did, and when

February 28, 2025 — FDA issued class-wide labeling changes for all approved testosterone products after reviewing two sets of evidence: the TRAVERSE trial, and required postmarket ambulatory blood-pressure studies.

From TRAVERSE, the agency recommended three labeling moves:

• Add the trial results to every testosterone product label.
• Keep the existing "Limitation of Use" language for age-related hypogonadism.
• Remove boxed-warning language about an increased risk of adverse cardiovascular outcomes.

From the blood-pressure studies, it required two more: product-specific blood-pressure information for products that already had those studies, and a new warning about increased blood pressure for products that did not already carry one.

Testosterone remains approved, in the FDA's words, solely for men who lack or have low testosterone in conjunction with an associated medical condition. That includes the gels, injections, and other formulations on the US market. The list is the agency's, not a menu of what I prescribe.

The boxed cardiovascular warning came off. The limitation for "low T of aging" stayed. A blood-pressure warning was added. None of those three sentences is optional if you want an accurate picture.

Where the warning came from

This did not start with TRAVERSE. It started with reports.

January 2014 — FDA issued a Drug Safety Communication warning of reported risks of stroke, heart attack, and death in men taking FDA-approved testosterone products.

September 2014 — A joint advisory committee met after those reports increased. The agency later pointed to that meeting as the origin of a recommendation for an industry-wide cardiovascular trial in men with age-related hypogonadism.

March 2015 — Another Drug Safety Communication: labeling changes, and a caution against using testosterone for low T due to aging.

That sequence is how a generation of men were talked out of a conversation. Some of them had a real diagnosis. Some of them had a birthday and a number on a commercial. The label did not separate those two groups well, and primary care often did not either.

TRAVERSE was the trial that sequence produced. Results were submitted to FDA in 2023. Published in the New England Journal of Medicine, it randomized 5,246 men aged 45 to 80 — symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and established cardiovascular disease or high risk — to a 1.62% testosterone gel or placebo. The primary endpoint was major adverse cardiac events: death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke.

A primary event occurred in 182 men (7.0%) on testosterone and 190 men (7.3%) on placebo. Hazard ratio 0.96, 95% confidence interval 0.78 to 1.17. The trial met its noninferiority design. Mean treatment was about 22 months; mean follow-up about 33 months.

FDA's summary of that result is the sentence that matters for the label: there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.

Two caveats belong next to that sentence. TRAVERSE enrolled men who already had disease or high risk, on a gel, with a documented diagnosis. It is not a study of every man who ever searched "low T." And a finding of no increase in that composite is not a finding that testosterone has no cardiovascular effects of any kind. The blood-pressure work is the proof of that.

What did not change

This is the part that gets skipped when the headline is "FDA says testosterone is safe," so I will put it plainly.

The Limitation of Use for age-related hypogonadism stayed. FDA still does not treat "low testosterone because you got older" as an approved indication by itself. The approved use is low or absent testosterone together with an associated medical condition. That was true in 2015. It is true after February 2025.

I treat documented hypogonadism. Labs, symptoms, history. I do not treat a birthday. Wanting to feel 32 is not a protocol. A real deficit on the chart is a different conversation, and it always was.

The boxed cardiovascular language came off. Information about cardiovascular risk did not vanish from medicine. Blood pressure went the other direction: it was added as a class-wide warning after ambulatory studies showed an increase with testosterone products. In my practice that is not a footnote. We measure it. A man whose pressure is already a problem is not someone I start on a protocol to see what happens.

There are men I will not treat. Personal history, hematocrit, prostate evaluation including PSA as indicated, fertility goals, and the rest of the chart still decide that. A labeling change does not override a contraindication.

What this means for the man sitting in my office

If you asked about TRT and were told it causes heart attacks, without a conversation about whether you meet criteria for hypogonadism, what your blood pressure is, or what your labs show, the ground has shifted. It has not shifted into a blank check.

TRAVERSE is relevant to that old no. It is not a substitute for a diagnosis. It is not permission to skip blood pressure. It is not a reason to ignore fertility if you still want children.

Exogenous testosterone suppresses the signal that tells the testes to make testosterone and sperm. That is expected physiology. Depending on your labs and your goals, I use HCG or enclomiphene — not as a default stack on every protocol, and not as a guarantee of a pregnancy. Fertility and testicular function are part of how I think about TRT. If that is on the table for you, say so in the first conversation, not six months in.

Estradiol is on the men's panel. Some testosterone converts to it. We measure it and we watch it. It is not a separate product, and I do not chase a number I invented for a blog post.

How we handle it here

Nothing about my process changed on February 28, 2025, because it was never built on the boxed warning in the first place. It is built on labs.

Every protocol starts with a full panel, priced between $100 and $345 — more than 70 factors, including total and free testosterone, estradiol, SHBG, LH, FSH, PSA, a CBC, and a metabolic panel. I go through the results with you myself before anything is prescribed. We repeat at six to eight weeks.

Medications come from licensed compounding pharmacies. This is a cash-pay practice. The only price published here is the panel.

TRT by telehealth is available to Florida residents only. If you are outside Florida, you are welcome at the Oakland Park clinic in person — 1164 E. Oakland Park Blvd., Suite 202 — and patients from any state are welcome there.

You can read the service page at Testosterone / TRT. This article is the labeling conversation. That page is the process.

Questions I get asked

So the FDA now says TRT is safe?
No. The agency removed boxed-warning language about cardiovascular harm that TRAVERSE did not support in men treated for hypogonadism. It added a blood-pressure warning. Whether TRT is right for you still depends on your history, your labs, and your contraindications.

I'm 58 and my testosterone is "low for my age." Is that enough?
Not by itself. FDA still does not approve testosterone for low T due to aging alone. I am looking for documented hypogonadism, not a comparison to your 25-year-old self on a lab printout. Bring the symptoms. We will run the panel. Then we will talk.

What about blood pressure?
The new warning is real. Testosterone can raise it. We check it, and we keep checking it. If your pressure is not in a place I am willing to work with, we deal with that first.

Will TRT make me infertile?
It can suppress sperm production. That is how the axis works when you put testosterone in from the outside. If fertility matters, we discuss HCG or enclomiphene up front, based on labs and goals. Juvenis is a hormone clinic, not a fertility center.

What about prostate and hematocrit?
Both stay on the table. PSA as indicated. Hematocrit on the CBC. I will not invent a cutoff in this article. I will tell you what your numbers mean in the room, and there are results that stop a protocol.

Can I do this if I don't live in Florida?
TRT telehealth is Florida residents only. In-person at Oakland Park is open to any state. That has not changed.